Search clinical trials for: gp100:280-288(288V) peptide vaccine

Total 36 results

Bristol-Myers Squibb
National Cancer Institute (NCI)

Withdrawn

Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma

Melanoma (Skin)
University of Virginia
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; National Cancer Institute (NCI); Medarex

Completed

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

Melanoma (Skin)

United States
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; National Cancer Institute (NCI); Medarex

Completed

Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558

Melanoma (Skin)

United States
AbbVie (prior sponsor, Abbott)

Completed

Efficacy and Safety Study for Cognitive Deficits in Adult Subjects With Schizophrenia

Cognitive Deficits in Schizophrenia

United States
AbbVie

Completed

A Multiple Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-288 in Stable Subjects With Schizophrenia

Schizophrenia
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)

Completed

Dendritic Cell Vaccination During Lymphoid Reconstruction

Intraocular Melanoma | Melanoma (Skin)

United States
Centre René Gauducheau

Completed

TF2- Small Cell Lung Cancer Radio Immunotherapy

Small Cell Lung Cancer | CEA-expressing Non Small Cell Lung Carcinoma (NSCLC)

France
Nantes University Hospital

Terminated

Pretargeted Radioimmunotherapy in Metastatic Colorectal Cancer (RITCOLON)

Metastatic Colorectal Cancer

France
Nantes University Hospital
Institut National de la Santé Et de la Recherche Médicale, France; Gilead Sciences

Completed

ImmunoTEP for Patients With Medullary Thyroid Carcinoma. (iTEP-CMT)

Medullary Thyroid Carcinoma

France
Nantes University Hospital
Institut National de la Santé Et de la Recherche Médicale, France; Gilead Sciences

Completed

ImmunoTEP au 68-Ga- IMP-288 for Patients With a Recurrence of HER2 Negative Breast Carcinoma Expressing CEA (iTEPsein)

HER2 Negative Breast Carcinoma Expressing CEA

France
National Cancer Institute (NCI)

Completed

Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery

Stage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage IV Melanoma

Melanoma (Skin)

United States
University of Southern California
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Intraocular Melanoma | Melanoma (Skin)

United States
Radboud University Medical Center

Completed

Study of Pretargeted Radioimmunotherapy of a Anti-CEA Bispecific Antibody and Lu177-labeled Peptide in Colorectal Cancer (PRIT2008)

Colorectal Neoplasms

Netherlands
Nantes University Hospital

Completed

ImmunoTEP With 68-Ga in Metastatic Colo Rectal Cancer (iTEP Colon)

Metastatic Colorectal Cancer

France
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)

Completed

Adenovirus CCL-21 Transduced MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured

Melanoma (Skin)

United States
Bristol-Myers Squibb

Completed

MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma

Melanoma | Metastases

United States, Canada, Netherlands, United Kingdom, Germany, Chile, Belgium, France, South Africa, Argentina, Brazil, Hungary, Switzerland
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC

Completed

Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine

Melanoma

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
The Netherlands Cancer Institute

Recruiting

Body Surface Area-based vs Concentration-based Dosing of Cisplatin for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Women With Advanced Ovarian Cancer (CisCon)

Fallopian Tube Carcinoma | Peritoneal Cancer | FIGO Stage III Ovarian Cancer

Netherlands
Memgen, Inc.
H. Lee Moffitt Cancer Center and Research Institute; Duke Cancer Institute

Recruiting

MEM-288 Oncolytic Virus Alone and in Combination With Nivolumab in Solid Tumors Including Non-Small Cell Lung Cancer

Melanoma | Head and Neck Cancer | Pancreatic Cancer | Solid Tumor | Non Small Cell Lung Cancer | Metastatic Cancer | Triple Negative Breast Cancer | Advanced Cancer | Merkel Cell Carcinoma | Cutaneous Squamous Cell Carcinoma

United States
Institute of Medical Biology, Chinese Academy of...
West China Second University Hospital; Yunnan Center for Disease Control and...

Completed

Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 in People Aged ⩾60 Years

COVID-19

China
University of Southern California
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

Recurrent Melanoma | Stage IV Melanoma | Mucosal Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage... and other conditions

United States
AbbVie (prior sponsor, Abbott)

Completed

Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease

Alzheimer's Disease

Russian Federation, Ukraine
National Cancer Institute (NCI)

Completed

Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
University of Southern California

Completed

Novel Adjuvants for Peptide-Based Melanoma Vaccines

Melanoma

United States
Institute of Medical Biology, Chinese Academy of...
West China Second University Hospital; Yunnan Center for Disease Control and...

Completed

Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19

COVID-19

China
Canadian Immunization Research Network
Massachusetts General Hospital; CHU de Quebec-Universite Laval; McGill University... and other collaborators

Active, not recruiting

Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity (MOSAIC)

COVID-19

Canada
University of Virginia
National Cancer Institute (NCI)

Completed

Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma

Melanoma (Skin)

United States
Novo Nordisk A/S

Completed

A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.

Diabetes Mellitus, Type 2

United States, Poland, Slovakia, Canada, Slovenia, Greece, Czechia
University of Copenhagen

Completed

GLP-1 Response and Effect in Individuals With Obesity Causing Genetic Mutations

Obesity

Denmark
Hvidovre University Hospital
University of Copenhagen; The Novo Nordic Foundation

Unknown

Treatment of Low Blood Sugar With Glucagon Among Patients With Type 1 Diabetes (GluST1)

Diabetes Mellitus, Type 1

Denmark
German Cancer Research Center
Charite University, Berlin, Germany; Roche Pharma AG; Johannes Gutenberg University... and other collaborators

Recruiting

A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas (INTERCEPT-H3)

Newly Diagnosed H3-mutated Glioma

Germany
National Institute of Mental Health (NIMH)

Completed

CATIE- Schizophrenia Trial

Schizophrenia

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Recruiting

TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

Stage II Breast Cancer AJCC v6 and v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | Breast Adenocarcinoma

United States

Search clinical trials for: gp100:280-288(288V) peptide vaccine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations